Compare iShares MSCI Canada (TSX) (EWC) vs GSK plc (GSK) Price & Performance

EWC trades at $61.72, up 0.35% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF remains focused on Canadian equities, showing double-digit returns in 2026 but trailing the S&P 500. Recent news highlights trade tensions with the U.S., including potential 50% tariffs on Canadian goods, though key sectors like energy are exempt.

Outlook is mixed: bullish technicals and strong 2026 performance support upside, but trade war risks and overbought conditions pose near-term headwinds. Investors should weigh Canada's economic resilience against tariff uncertainties for balanced exposure.

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.